(Source: May 24 2012; Stemedica Cell Technologies, Inc.)
Stemedica International, Epalinges, Switzerland, a wholly owned subsidiary of Stemedica Cell Technologies, Inc. (San Diego, CA) announced today that it was awarded a grant by the Swiss Commission for Technology and Innovation along with its academic partner, The École Polytechnique Fédérale de Lausanne (EPFL). The 584,522 CHF (approx. 620,000 USD) grant is focused on the use of EPFL’s advanced imaging capabilities along with Stemedica’s ischemic tolerant stem cells and stem cell factors in transgenic mouse models of Alzheimer’s disease. The basic research supports Stemedica’s clinical trial advancement for Alzheimer’s disease for both Switzerland and the United States.
“We are pleased that we will be collaborating with one of the world’s leading technical academic institutions,” said Nikolai Tankovich, MD, PhD, Executive Chairman of Stemedica International. “We will be able to see the therapeutic potential of our ischemia tolerant neural and mesenchymal cells, as well as the impact of our stem cell factors on the amyloid plaque pathology and brain vascularization associated with Alzheimer’s disease.”
EPFL has developed sophisticated imaging methods that allow for the visualization of amyloid plaques without the need of injecting amyloid-binding dyes / contrast agents. In addition to visualizing amyloid plaques, the precise, femtosecond laser system allows imaging of quantitative blood flow and other critical functional parameters.
Professor Theo Lasser, Head of Laboratoire d’Optique Biomedicale (LOB), EPFL, commented, “We are excited to collaborate with the world’s leading manufacturer of allogeneic stem cells and apply our methods of Optical Coherent Microscopy developed at LOB, EPFL to potentially find a cure for Alzheimer’s disease.”
Tristan Bolmont, PhD, of EPFL will lead the research project, along with Alexei Lukashev, PhD., Director of the Laser Stem Cell Division, Stemedica. Dr. Bolmont commented on the scope of the project, “The scale of this project, treating and imaging more than 140 subjects, will allow us to make the correlations that are critical to understanding the pathophysiology of this disease. Furthermore, we will better understand the biodistribution and the mechanism of action of Stemedica’s ischemia tolerant neural and mesenchymal stem cells and how they affect the Alzheimer’s altered brain.”
According to Roger Howe, PhD, President of Stemedica International, “The Swiss government is being remarkably progressive in bridging the gap between bench top research and translational medicine. We greatly appreciate their support in documenting stem cell effectiveness in neurological diseases.”
About Stemedica, Stemedica Cell Technologies, Inc., is a specialty bio-pharmaceutical company committed to the manufacturing and development of best-in-class allogeneic adult stem cells and stem cell factors for use by approved research institutions and hospitals for pre-clinical and clinical (human) trials. The company is a government licensed manufacturer of clinical grade stem cells and is approved by the FDA for its clinical trials for ischemic stroke. Stemedica is currently developing regulatory pathways for a number of medical indications using adult allogeneic stem cells. The Company is headquartered in San Diego, California.
About The École Polytechnique Fédérale de Lausanne (EPFL) The EPFL is one of the two Swiss Federal Institutes of Technology is located in Lausanne, Switzerland. The school was founded by the Swiss Federal Government with the stated mission to (a) educate engineers and scientists, (b) be a national center of excellence in science and technology, (c) provide a hub for interaction between the scientific community and industry. The sister institution in the German-speaking part of Switzerland is the Eidgenössische Technische Hochschule Zürich (ETH Zürich or ETHZ). Associated with several specialized research institutes, the two sister institutes form the ETH Domain. EPFL is ranked among the top academic institutions in the world.